Thu. 29 Feb 2024, 8:48am ET
Benzinga
Biotech, News, Events, General
- Long-term CNM-Au8 treatment demonstrated significant and clinically meaningful improvement of vision as measured by low contrast letter acuity (LCLA), an assessment of visual function in people living with multiple sclerosis (MS), through 35 months from randomization, p<0.0001
- Long-term CNM-Au8 treatment demonstrated improvement of cognition, measured by the Symbol Digit Modality Test (SDMT), through 35 months from randomization, p<0.0001
- Treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8 and no significant safety findings were reported
- Treatment was well-tolerated, without a single serious adverse event attributed to CNM-Au8 and no significant safety findings were reported